Vismodegib: in locally advanced or metastatic basal cell carcinoma. - Wikidata - awgldk - TriplyDB

Vismodegib: in locally advanced or metastatic basal cell carcinoma.

Vismodegib: in locally advanced or metastatic basal cell carcinoma.

http://www.wikidata.org/entity/Q34032755

about

Profile of vismodegib and its potential in the treatment of advanced basal cell carcinoma Oculoplastic aspects of ocular oncology.Direct long bone invasion by Basal cell carcinoma: a case report and review of the literature.Vismodegib in the treatment of basal cell carcinoma: indications for clinical practice.GLI2 is a novel therapeutic target for metastasis of osteosarcoma.Neoadjuvants for basal cell carcinoma. When and why?Vismodegib: a guide to its use in locally advanced or metastatic basal cell carcinoma.

P2860

Q37079100-C3812BC7-56CC-48AD-A821-4F0ACB2996BA Q38063746-5121E81D-7C3B-49FE-A0B7-B9F054A80F95 Q38170118-E065F31A-2053-47D9-B662-55FAC329C697 Q38465861-CF98D295-D35B-45BD-A4AF-02306CF2C16F Q38969673-F95571E1-F7A8-4661-94DC-9C2CA8903F3F Q42473894-5AACA72A-4121-47E3-849F-9BCE8E34A15F Q42519496-F93050EE-FE3D-498B-B156-22F4D4D1F5F6

P2860

Vismodegib: in locally advanced or metastatic basal cell carcinoma.

http://www.wikidata.org/entity/Q34032755

description

2012 nî lūn-bûn

@nan

2012 թուականի Յուլիսին հրատարակուած գիտական յօդուած

@hyw

2012 թվականի հուլիսին հրատարակված գիտական հոդված

@hy

2012年の論文

@ja

2012年論文

@yue

2012年論文

@zh-hant

2012年論文

@zh-hk

2012年論文

@zh-mo

2012年論文

@zh-tw

2012年论文

@wuu

name

Vismodegib: in locally advanced or metastatic basal cell carcinoma.

@ast

Vismodegib: in locally advanced or metastatic basal cell carcinoma.

@en

Vismodegib: in locally advanced or metastatic basal cell carcinoma.

@nl

type

label

Vismodegib: in locally advanced or metastatic basal cell carcinoma.

@ast

Vismodegib: in locally advanced or metastatic basal cell carcinoma.

@en

Vismodegib: in locally advanced or metastatic basal cell carcinoma.

@nl

prefLabel

Vismodegib: in locally advanced or metastatic basal cell carcinoma.

@ast

Vismodegib: in locally advanced or metastatic basal cell carcinoma.

@en

Vismodegib: in locally advanced or metastatic basal cell carcinoma.

@nl

P1433

Q34032755-C4CD2348-CAE6-4C50-BA34-F48C34EB45AF

P1476

Q34032755-05F205DB-D45A-4CED-A0E1-D79926A69BE9

P2860

Q34032755-01B04B10-5A19-4868-AE26-CB96C57F36F7

Q34032755-06E17DFF-93E6-423E-8FDA-B92A658703F0

Q34032755-3DFD550D-0E26-465D-AB49-B71FC7348FC1

Q34032755-5F706577-B150-4A59-823D-50184E5A2378

Q34032755-6736D07A-1AF4-49C4-84E1-025105CC6C9B

Q34032755-839AF51A-190A-45FE-8C9D-FAD713720FF9

Q34032755-88394D26-AD79-4C3A-BA74-E7224010987D

Q34032755-8CA12DBF-AB79-4BD2-82D9-F4E7DFE58DB3

Q34032755-8F2021C2-E28D-49D0-BEEC-19416118131A

Q34032755-DB2F4691-BF48-4444-A01E-96ACB5014A63

P2888

Q34032755-6106FC4B-9C53-46AE-8149-140B88FC2C90

P304

Q34032755-D884649A-4048-45EF-8FA2-688F0970F38C

P31

Q34032755-92F467A1-B615-4A4C-9D31-8F9326C69377

P356

Q34032755-7A2A10B9-4CD1-46B3-8FC7-3DBAAAEED223

P433

Q34032755-BE84B905-1C19-4FF9-A58F-515F79A59BE4

P478

Q34032755-6A8C0079-4C59-4B72-9BB5-1D436E2D122E

P50

Q34032755-3D0E99FB-3F20-4D17-A1CB-1C8472C3376A

P577

Q34032755-46F4C2D8-FB7A-4F39-8DF7-7378586B63B3

P6179

Q34032755-2162F745-EEDA-4D8C-9C74-C7853CFF0A51

P698

Q34032755-A1D60A45-DA41-4B07-B2EE-F4435D1611E7

P921

Q34032755-DD36DB60-6114-4607-8EE4-E1335C54CEF8

P356

11209590-000000000-00000

P1433

P1476

Vismodegib: in locally advanced or metastatic basal cell carcinoma.

@en

P2860

Pharmacokinetics of hedgehog pathway inhibitor vismodegib (GDC-0449) in patients with locally advanced or metastatic solid tumors: the role of alpha-1-acid glycoprotein binding

Inhibition of the hedgehog pathway in advanced basal-cell carcinoma.

Efficacy and safety of vismodegib in advanced basal-cell carcinoma.

Phase I trial of hedgehog pathway inhibitor vismodegib (GDC-0449) in patients with refractory, locally advanced or metastatic solid tumors.

Hedgehog signaling: networking to nurture a promalignant tumor microenvironment.

Assessing current treatment options for patients with severe/advanced basal cell carcinoma.

Identification, characterization, and implications of species-dependent plasma protein binding for the oral Hedgehog pathway inhibitor vismodegib (GDC-0449).

GDC-0449-a potent inhibitor of the hedgehog pathway.

A paracrine requirement for hedgehog signalling in cancer.

Treatment of medulloblastoma with hedgehog pathway inhibitor GDC-0449

P2888

11209590-000000000-00000

P304

1535-1541

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.2165/11209590-000000000-00000

http://www.w3.org/2001/XMLSchema#string

P433

11

http://www.w3.org/2001/XMLSchema#string

P478

72

http://www.w3.org/2001/XMLSchema#string

P50

Gillian M Keating

P577

2012-07-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P6179

1052074973

http://www.w3.org/2001/XMLSchema#string

P698

22788238

http://www.w3.org/2001/XMLSchema#string

P921